PMEG is an inhibitor targeting the nuclear DNA polymerases α, δ, and ε (DNA polymerases α/δ/ε), leading to DNA chain termination and suppression of DNA synthesis, which induces cytotoxicity in proliferating cells. This acyclic nucleoside phosphonate converts intracellularly to its active phosphorylated metabolite, PMEG diphosphate. In rodent models, PMEG demonstrates activity against leukemia and melanoma. Due to its poor cellular permeability, its prodrug form is known as Rabacfosadine (GS-9219). PMEG exhibits antiviral activity against several DNA virus infections, including murine cytomegalovirus (MCMV) and human cytomegalovirus (HCMV). It is also investigated for non-Hodgkin's lymphoma research.

9-(2-Phosphonylmethoxy)ethylguanine